New International Study Highlights IOP-Lowering Performance Of Glaukos iStent Inject® Trabecular Micro-Bypass In Standalone Procedure

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that in a study published in Advances in Therapy, 100% of 57 phakic eyes with open-angle glaucoma achieved a ≥ 20% reduction in unmedicated intraocular pressure (IOP) one year after implantation of the iStent inject®Trabecular Micro-Bypass in a standalone procedure. P...